PopVax is designing a personalized mRNA cancer vaccine for one man with stage IV pancreatic cancer, and has put his tumor data and its full vaccine design online so scientists anywhere can check and improve it before it is made.

Key Takeaways

  • The vaccine is for Yashdeep Bindal, who was diagnosed with stage IV pancreatic cancer at 32, just after his daughter was born
  • PopVax published his tumor sequencing data, its code and its lead vaccine design on GitHub, with his consent
  • The design packs 24 targets from his tumor into a single mRNA vaccine
  • Outside experts can suggest changes before PopVax manufactures it at its RNA Foundry in Hyderabad, India

PopVax launched the project on Wednesday. "We want external experts to review our design and make their own contributions before we manufacture it at the RNA Foundry," co-founder Soham Sankaran said on X.

A Vaccine Built From One Tumor

Bindal was diagnosed in January 2025. PopVax says he has authorized the public release of his data so that people who work on cancer vaccines, antigen discovery or immunotherapy can download it and weigh in.

The lead design is one mRNA sequence that teaches the immune system to spot 24 features of his cancer: 12 mutations, five abnormal gene splices, five cancer-linked proteins and two fused genes. To avoid targeting healthy tissue, the team compared his tumor DNA with DNA from his white blood cells and dropped seven targets that also showed up in his normal cells.

Also Read: Doctors Waste 28 Hours A Week On Paperwork, So Google Cloud Built Gemini To Do It

How To Contribute

Researchers can fork the GitHub repository, add their own design with the reasons for each choice and open a pull request, or email the team. PopVax is asking which targets to include, which signaling parts to use and what it may have missed.

Who Is Behind It

PopVax is an Indian RNA vaccine company backed by the Gates Foundation, Good Ventures, Ethereum co-founder Vitalik Buterin and the US Biomedical Advanced Research and Development Authority. Its first mRNA vaccine, a COVID-19 candidate built at the same facility, entered a clinical trial in Australia this year.

Personalized mRNA cancer vaccines are still experimental. PopVax points to early results from Merck and Moderna in melanoma and from BioNTech and Genentech in pancreatic cancer, but says approvals may come too late for many patients alive today. The vaccine for Bindal has not been made yet, and PopVax has not said when it will be given.

Read Next: RoboScript Teaches Robots A Task From One Demo, Beating Trained Rivals By 20 Points

Originally published on Fathom News.